Celyad Oncology Statistics
Total Valuation
Celyad Oncology has a market cap or net worth of 14.45 million. The enterprise value is 14.50 million.
| Market Cap | 14.45M |
| Enterprise Value | 14.50M |
Important Dates
The next estimated earnings date is Thursday, April 2, 2026.
| Earnings Date | Apr 2, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 44.76M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +17.90% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 0.48% |
| Owned by Institutions (%) | 0.04% |
| Float | 17.48M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 66.14 |
| PB Ratio | -3.97 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -1.91 |
| EV / Sales | 65.68 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.66
| Current Ratio | 0.66 |
| Quick Ratio | 0.42 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -64.40 |
Financial Efficiency
Return on equity (ROE) is -7,871.95% and return on invested capital (ROIC) is -405.75%.
| Return on Equity (ROE) | -7,871.95% |
| Return on Assets (ROA) | -43.41% |
| Return on Invested Capital (ROIC) | -405.75% |
| Return on Capital Employed (ROCE) | -325.42% |
| Weighted Average Cost of Capital (WACC) | 8.32% |
| Revenue Per Employee | 12,135 |
| Profits Per Employee | -421,152 |
| Employee Count | 19 |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -38.78% in the last 52 weeks. The beta is 0.73, so Celyad Oncology's price volatility has been lower than the market average.
| Beta (5Y) | 0.73 |
| 52-Week Price Change | -38.78% |
| 50-Day Moving Average | 9.78 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 33.11 |
| Average Volume (20 Days) | 1,045 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Celyad Oncology had revenue of 218,438 and -7.58 million in losses. Loss per share was -0.18.
| Revenue | 218,438 |
| Gross Profit | 205,520 |
| Operating Income | -7.56M |
| Pretax Income | -7.58M |
| Net Income | -7.58M |
| EBITDA | -7.38M |
| EBIT | -7.56M |
| Loss Per Share | -0.18 |
Balance Sheet
The company has 927,775 in cash and 975,925 in debt, with a net cash position of -48,150.
| Cash & Cash Equivalents | 927,775 |
| Total Debt | 975,925 |
| Net Cash | -48,150 |
| Net Cash Per Share | n/a |
| Equity (Book Value) | -3.64M |
| Book Value Per Share | -0.09 |
| Working Capital | -1.48M |
Cash Flow
| Operating Cash Flow | -7.19M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | 94.09% |
| Operating Margin | -3,462.37% |
| Pretax Margin | -3,470.43% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Celyad Oncology does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -17.90% |
| Shareholder Yield | -17.90% |
| Earnings Yield | -52.47% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Celyad Oncology has an Altman Z-Score of -93.11 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -93.11 |
| Piotroski F-Score | 3 |